SPC362
Daratumumab, cyclophosphamide, bortezomib og dexamethasone
Status:
UmsóknApplication date:
7.12.2021Application published:
15.1.2022
Max expiry date:
25.9.2032Medicine name:
DARZALEXMedicine for children:
No
Timeline
Today
7.12.2021Application
15.1.2022Publication
25.9.2032Expires
Marketing license
Foreign authorization number:
EU/1/16/1101Date:
21.6.2021
Owner
Name:
Genmab A/SAddress:
Carl Jacobsens Vej 30, Valby DK
Agent
Name:
Tego IP ehf.Address:
Pósthólf 8129, 128 Reykjavík
Patent
Number:
EP2081595